What about the controversy regarding rosiglitazone;Le point sur la controverse à propos de la rosiglitazone

Revue Medicale de Liege

Volumn 62, Issue 9, 2007, Pages 560-565

  Scheen, A J ^a,b   De Flines, J ^b   Paquot, N ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular mortality; Diabetes; Meta analysis; Myocardial infarction; Rosiglitazone; Thiazolidinedione

Indexed keywords

GLIBENCLAMIDE PLUS METFORMIN; INSULIN SENSITIZING AGENT; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; ORAL ANTIDIABETIC AGENT; PLACEBO; ROSIGLITAZONE; SULFANILAMIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ADVISORY COMMITTEE; ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COMPARATIVE STUDY; CONSULTATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA BASE; DIABETIC PATIENT; FOOD AND DRUG ADMINISTRATION; HUMAN; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PROGNOSIS; PROSPECTIVE STUDY; REGISTER; SYSTEMATIC REVIEW; UNITED STATES; CHEMICALLY INDUCED DISORDER; HEART DISEASE; RISK ASSESSMENT;

ADVISORY COMMITTEES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HEART DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; RISK ASSESSMENT; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 38449092663     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Yki-Järvinen H. - Thiazolidinediones. N Engl J Med, 2004, 351, 1106-1118.
2. Scheen AJ, Paquot N. - Récepteurs PPAR-γ, nouvelle cible thérapeutique dans les pathologies métaboliques et cardio-vasculaires. Rev Med Liège, 2005, 60, 89-95.
3. Nathan DM, Buse JB, Davidson MB, et al. - Management of hyperglycemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy : a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2006, 29, 1963-1972.
4. Kahn SE, Haffner SM, Heise MA, et al for the ADOPT Study Group. - Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006, 355, 2427-2443.
5. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. - Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev, 2007 (3): CD006063.
6. Chiquette E, Ramirez G, DeFronzo R. - A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med, 2004, 164, 2097-3104.
7. Scheen AJ, Van Gaal LF. - Le diabète de type 2 au coeur du syndrome métabolique : plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571.
8. Riche DM, Valderrama R, Henyan NN. - Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a metaanalysis. Diabetes Care, 2007, 30, 384-388.
9. Rosmarakis ES, Falagas ME. - Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J, 2007, 154, 144-150.
10. Scheen AJ, Lefèbvre PJ. - L'étude PROactive : prévention secondaire des accidents cardio-vasculaires par la pioglitazone chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 896-901.
11. Dormandy J, Charbonnel B, Eckland DJA, et al. - Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events) : a randomised controlled trial. Lancet, 2005, 366, 1279-1289.
12. Yki-Järvinen H. - The PROactive study : some answers, many questions. Lancet, 2005, 366, 1241-1242.
13. Erdmann E, Dormandy JA, Charbonnel B, et al, on behalf of the PROactive Investigators. - The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. J Am Coll Cardiol, 2007, 49, 1772-1780.
14. Nesto RW, Bell D, Bonow RO, et al. - Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care, 2004, 27, 256-263.
15. De Flines J, Scheen AJ.- Glitazones et insuffisance cardiaque : les point sur les études PROactive, ADOPT, DREAM et RECORD. Rev Med Suisse. 2007, 3, 1876-1883.
16. Nissen SE, Wolski K. - Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med, 2007, 356, 2457-2471.
17. Home PD, Pocock SJ, Beck-Nielsen H, et al. - Rosiglitazone Evaluated for Cardiovascular Outcomes - An interim analysis. N Engl J Med, 2007, 357, 28-38.
18. Rosen CJ. - The rosiglitzone story - lessons from an FDA Advisory Committee Meeting. N Engl J Med, 2007, 357, 844-846.
19. Krall RL. - Cardiovascular safety of rosiglitazone. Lancet, 2007, 369, 1995-1996.
20. Kazi D. - Rosiglitazone and implications for pharmacovigilance. BMJ, 2007, 334, 1233-1234.
21. Fuster V, Farkouh ME. - Faster publication isn't always better. Nature Clin Pract, 2007, 4, 345.
22. Diamond GA, Bax L, Kaul S. - Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007. 8. August 6 (Epub ahead of print).
23. Scheen AJ. - Comment j'explore... les secrets d'une méta-analyse. Rev Med Liège. 2003, 58, 41-46.
24. Psaty BM, Furberg CD. - Rosiglitazone and cardiovascular risk. N Engl J Med, 2007, 356, 2522-2524.
25. Home PD, Pocock SJ, Beck-Nielsen H, et al. - Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) : study design and protocol. Diabetologia, 2005, 48, 1726-1735.
26. Scheen AJ. - Comment j'explore ... les critères de jugement dans les essais cliniques : réflexion à propos d'études récentes de prévention cardio-vasculaire. Rev Med Liège. 2006, 61, 260-266.
27. Nathan DM. - Rosiglitazone and cardiotoxicity - Weighing the evidence. N Engl J Med, 2007, 357, 64-66.
28. Psaty BM, Furberg CD. - The Record on rosiglitazone and the risk of myocardial infarction. N Engl J Med, 2007, 357, 67-69.
29. Drazen JM, Morrissey S, Curfman GD. - Rosiglitazone - Continued uncertainty about safety. N Engl J Med. 2007, 357, 63-64.
30. Johannes CB, Koro CE, Quinn SG, et al. - The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf, 2007, 16, 504-512.
31. McAfee AT, Koro C, Landon J, et al. - Coronary heart disease outcomes in patients receiving antidiabetic agents Pharmacoepidemiol Drug Saf 2007, 16, 711-725.
32. FDA Advisory Committee : http://www.fda.gov/ohrms/dockets/ac/cder07. htm#EndocrinologicMetabolic
33. Scheen A.J. - Combined thiazolidinedione-insulin therapy. Should we be concerned about safetv? Drug Safety. 2004, 27, 841-856.